Findings

What do systematic reviews say?

47 questions · 47 findings · 11 reviews

No studies found 2 · 4.3%GRADE not reported 1 · 2.1%Very low 21 · 44.7%Low 14 · 29.8%Moderate 9 · 19.1%High 0 · 0%

Adverse events · maintenance of remission in Crohn's disease

It is very uncertain whether 6‐Mercaptopurine changes adverse events compared with methotrexate (very low certainty).

1 finding from 1 review

Azathioprine or 6‐mercaptopurine for maintenance of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
RR 0.65 [0.31, 1.38]
1 study · 57 participants
Very low

Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus

Oral ciclosporin showed no clear difference in adverse events: severe compared with oral azathioprine (low certainty).

1 finding from 1 review

Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
RR 0.89 [0.48, 1.65]
1 study · 89 participants
Low

Adverse events (Ardizzone 2003) · adult patients with refractory Crohn's disease

It is very uncertain whether methotrexate changes adverse events (Ardizzone 2003) compared with 6‐MP or azathioprine (very low certainty).

1 finding from 1 review

Methotrexate for induction of remission in refractory Crohn's disease 2014 · Cochrane Headline outcomes only
RR 2.43 [1.21, 4.89]
1 study · 54 participants
Very low

Adverse events: minor (hirsutism) · patients with cutaneous disease in systemic lupus erythematosus

Oral ciclosporin may leads to higher adverse events: minor (hirsutism) compared with oral azathioprine (low certainty).

1 finding from 1 review

Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
RR 9.83 [1.32, 72.95]
1 study · 89 participants
Low

Incidence of serious adverse events · adults with alopecia areata

1 finding from 1 review

Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 154 participants
Very low

Serious adverse events · maintenance of remission in Crohn's disease

It is very uncertain whether 6‐Mercaptopurine changes serious adverse events compared with methotrexate (very low certainty).

1 finding from 1 review

Azathioprine or 6‐mercaptopurine for maintenance of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
RR 0.68 [0.17, 2.75]
1 study · 57 participants
Very low

Withdrawals due to adverse events · maintenance of remission in Crohn's disease

It is very uncertain whether 6‐Mercaptopurine changes withdrawals due to adverse events compared with methotrexate (very low certainty).

1 finding from 1 review

Azathioprine or 6‐mercaptopurine for maintenance of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
RR 0.68 [0.17, 2.75]
1 study · 57 participants
Very low